Skip to main content
Premium Trial:

Request an Annual Quote

Stanley Lapidus, Noubar Afeyan, Stephen Lombardi, Michael Dunham

Premium
Helicos shuffled some executives last week, with company co-founder and CEO Stanley Lapidus taking on the job of chairman from Noubar Afeyan and Stephen Lombardi moving up to the role of president while retaining his job as COO. Afeyan was named lead independent director on the company’s board. 
 
Lombardi was previously COO and vice president of Helicos. Prior to joining the company, he was a senior VP at Affymetrix and before that he spent 16 years at Applied Biosystems as an executive in the company’s DNA sequencing and genetic analysis business. 
 

 
BioForce NanoSciences has appointed Michael Dunham to its board of directors. Dunham previously was on the board of directors at Arryx Technology. He is chairman and owner of Workwise and Intercim, and he previously was senior VP of business development for Industrial & Financial Systems and was co-founder and CEO of Effective Management Systems.  

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.